Tag Archives: RXi Pharmaceuticals

August, 2018

16 August
RXi Pharmaceuticals Partners with Karolinska Institutet to Develop sd-rxRNA Compounds to Advance Immuno-Oncology Therapeutics

MARLBOROUGH, Mass., Aug. 15, 2018 /PRNewswire/ — RXi Pharmaceuticals Corporation (NASDAQ: RXII) a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (sd-rxRNA®) therapeutic platform today announced that it has entered into a research collaboration with the Karolinska Institutet in Stockholm, Sweden. This collaboration …
Share

27 March
RXi and MirImmune Enter Licensing Deal for RXi’s Technology for Development of Cell-Based Cancer Immunotherapies

RXi Pharmaceuticals and privately-held MirImmune have entered into a license agreement to use RXi’s novel and proprietary technology for development of cell-based cancer drugs. The companies announced that they have entered into an exclusive license agreement to RXi’s sd-rxRNA technology for use in developing innovative cell-based cancer immunotherapies. The collaboration …
Share